Citations

Clear

29 citation(s) found for "Moll, M".

A Polygenic Risk Score for Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormalities
Peljto, Anna L. , Xu, Hanfei , Debban, Catherine L., Chen, Xianfeng , Menon, Aravind , Putman, Rachel K. , Saferali, Aabida , Nishino, Mizuki , Hatabu, Hiroto , Hobbs, Brian D. , McDermott, Gregory C , Sparks, Jeffrey A. , Allen, Richard J. , Raby, Benjamin A. , Chun, Sung , Silverman, Edwin K. , Zamora, Ana, Ortega, Victor E. , Bleecker, Eugene R. , Meyers, Deborah A. , Rotter, Jerome I. , Fingerlin, Tasha E. , Hunninghake, Gary M. , Peljto, Anna L , Menon, Aravind , Zamora, Ana C., Garcia, Christine K , Sparks, Jeffrey A , McDermott, Gregory , Rotter, Jerome I , Hobbs, Brian D , Allen, Richard J , Hunninghake, Gary M , Moll, Matthew , Kim, John S. , Ghosh, Auyon , Hecker, Julian , Wain, Louise V , Tobin, Martin D. , Barr, R. Graham , Kaner, Robert J. , Rich, Stephen S. , Manichaikul, Ani , Dupuis, Josée , O’Connor, George T. , Schwartz, David A. , Cho, Michael H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 31, 2023 | Volume: 208 | Issue: 7 | Pages: 791-801

10.1164/rccm.202212-2257oc | PMID 37523715 Get It

Abstract Rationale In addition to rare genetic variants and the MUC5B locus, common genetic variants contribute to idiopathic pulmonary fibrosis (IPF) risk. The predictive power of common variants outside the MUC5B locus for IPF and interstitial lung abnormalities (ILAs) is unknown. Objectives We tested the predictive value of IPF polygenic risk scores (PRSs) with and without the MUC5B region on IPF, ILA, and ILA progression. Methods We developed PRSs that included (PRS-M5B) and excluded (PRS-NO-M5B) the MUC5B region (500-kb window around rs35705950-T) using an IPF genome-wide association study. We assessed PRS associations with area under the receiver operating characteristic curve (AUC) metrics for IPF, ILA, and ILA progression. Measurements and Main Results We included 14,650 participants (1,970 IPF; 1,068 ILA) from six multi-ancestry population-based and case–control cohorts. In cases excluded from genome-wide association study, the PRS-M5B (odds ratio [OR] per SD of the score, 3.1; P = 7.1 × 10−95) and PRS-NO-M5B (OR per SD, 2.8; P = 2.5 × 10−87) were associated with IPF. Participants in the top PRS-NO-M5B quintile had ∼sevenfold odds for IPF compared with those in the first quintile. A clinical model predicted IPF (AUC, 0.61); rs35705950-T and PRS-NO-M5B demonstrated higher AUCs (0.73 and 0.7, respectively), and adding both genetic predictors to a clinical model yielded the highest performance (AUC, 0.81). The PRS-NO-M5B was associated with ILA (OR, 1.25) and ILA progression (OR, 1.16) in European ancestry participants. Conclusions A common genetic variant risk score complements the MUC5B variant to identify individuals at high risk of interstitial lung abnormalities and pulmonary fibrosis.
American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing
Middeldorp, Saskia , Nieuwlaat, Robby , Kreuziger, Lisa Baumann , Coppens, Michiel , Houghton, Damon E. , James, Allison , Lang, Eddy , Moll, Stephan , Myers, Tarra, Bhatt, Meha , Zhang, Yuan , Schünemann, Holger J. , Iorio, Alfonso , Baumann Kreuziger, Lisa , Houghton, Damon E , James, Andra H , Colunga-Lozano, Luis E , Karam, Samer G , Zhang, Yuan , Wiercioch, Wojtek , Schünemann, Holger J , Iorio, Alfonso , Chai‐Adisaksopha, Chatree , Colunga‐Lozano, Luis Enrique , Wiercioch, Wojtek

Mayo Clinic

Blood Advances | May 17, 2023 | Volume: 7 | Issue: 22 | Pages: 7101-7138

10.1182/bloodadvances.2023010177 | PMID 37195076 Get It

Background Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). Whether testing helps guide management decisions is controversial. Objective These evidence-based guidelines from the American Society of Hematology (ASH) intend to support decision making about thrombophilia testing. Methods ASH formed a multidisciplinary guideline panel covering clinical and methodological expertise and minimizing bias from conflicts of interest. The McMaster University GRADE Centre provided logistical support, performed systematic reviews, and created evidence profiles and evidence-to-decision tables. The Grading of Recommendations Assessment, Development, and Evaluation approach (GRADE) was used. Recommendations were subject to public comment. Results The panel agreed on 23 recommendations regarding thrombophilia testing and associated management. Nearly all recommendations are based on very low certainty in the evidence due to modeling assumptions. Conclusions The panel issued a strong recommendation against testing the general population before starting combined oral contraceptives (COCs) and conditional recommendations for thrombophilia testing in the following scenarios: (a) patients with VTE associated with nonsurgical major transient or hormonal risk factors; (b) patients with cerebral or splanchnic venous thrombosis, in settings where anticoagulation would otherwise be discontinued; (c) individuals with a family history of antithrombin, protein C, or protein S deficiency when considering thromboprophylaxis for minor provoking risk factors and for guidance to avoid COCs/hormone replacement therapy; (d) pregnant women with a family history of high-risk thrombophilia types; and (e) patients with cancer at low or intermediate risk of thrombosis and with a family history of VTE. For all other questions, the panel provided conditional recommendations against testing for thrombophilia.
Cumulative group metrics: a new and efficient method to measure the scientific impact of research groups
Moll, Uta, Camp, Christopher L. , Bedi, Asheesh , Khoury, Anthony , Villinger, Sarah M., Higgins, Laurence D. , Wijdicks, Coen A. , Khoury, Anthony N , Camp, Christopher L. , Wijdicks, Coen A

Mayo Clinic

Annals of Medicine & Surgery | March 2, 2023 | Volume: 85 | Issue: 2 | Pages: 124-129

10.1097/ms9.0000000000000086 | PMID 36845784 Get It

Background: Various metrics have emerged for assessing scientific impact, most of which are based on complex calculations and, in many cases, are not freely available. Moreover, most of these metrics are not intended for assessing the scientific impact of research groups. Cumulative group metrics are proposed as an efficient and cost-effective strategy for measuring group scientific impact. Materials and methods: The authors collected peer-reviewed output in 2020 from two academic orthopedic surgery departments [University of Michigan (UM) and Mayo Clinic Rochester (MC)] and one medical device research department [Arthrex Inc. (AI)]. The sites evaluated the Cumulative Group Number of Publications (CGNP), Cumulative Journal Impact Factor (CJIF), Cumulative CiteScore (CCS), Cumulative SCImago Journal Rank (CSJR), and Cumulative Source Normalized Impact per Paper (CSNIP) for the three institutions. Results: In 2020, UM published 159 peer-reviewed studies, MC published 347 peer-reviewed studies, and AI supported 141 publications. The UM publications achieved a CJIF of 513, a CCS of 891, a CSJR of 255, and a CSNIP of 247. The MC publications achieved a CJIF of 956, a CCS of 1568, a CSJR of 485, and a CSNIP of 508. AI-supported publications achieved a CJIF of 314, a CCS of 598, a CSJR of 189, and a CSNIP of 189. Conclusion: The presented cumulative group metrics are an effective tool to assess the scientific impact of a research group. The cumulative submetrics can further evaluate research groups compared with other departments due to field normalization. Department leadership and funding agencies can utilize these metrics to evaluate research output quantitatively and qualitatively.
A Metabolomic Severity Score for Airflow Obstruction and Emphysema
Godbole, Suneeta , Pratte, Katherine , Hill, Andrew , Hastie, Annette T. , Peters, Stephen P. , Gregory, Andrew , Ortega, Victor E. , DeMeo, Dawn L. , Bhatt, Surya P. , Wells, J. Michael , Barjaktarević, Igor , Stringer, Kathleen A. , Comellas, Alejandro P. , O’Neal, Wanda K. , Kechris, Katerina , Hill, Andrew , Gregory, Andrew , Barjaktarevic, Igor , Stringer, Kathleen A , Kechris, Katerina , O'Neal, Wanda K , Comellas, Alejandro P , Bhatt, Surya P , Wells, J Michael , Labaki, Wassim W. , Moll, Matthew , Cho, Michael H. , Bowler, Russell P.

Mayo Clinic

Metabolites | April 19, 2022 | Volume: 12 | Issue: 5 | Pages: 368

10.3390/metabo12050368 | PMID 35629872 Get It

Chronic obstructive pulmonary disease (COPD) is a disease with marked metabolic disturbance. Previous studies have shown the association between single metabolites and lung function for COPD, but whether a combination of metabolites could predict phenotype is unknown. We developed metabolomic severity scores using plasma metabolomics from the Metabolon platform from two US cohorts of ever-smokers: the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) (n = 648; training/testing cohort; 72% non-Hispanic, white; average age 63 years) and the COPDGene Study (n = 1120; validation cohort; 92% non-Hispanic, white; average age 67 years). Separate adaptive LASSO (adaLASSO) models were used to model forced expiratory volume at one second (FEV1) and MESA-adjusted lung density using 762 metabolites common between studies. Metabolite coefficients selected by the adaLASSO procedure were used to create a metabolomic severity score (metSS) for each outcome. A total of 132 metabolites were selected to create a metSS for FEV1. The metSS-only models explained 64.8% and 31.7% of the variability in FEV1 in the training and validation cohorts, respectively. For MESA-adjusted lung density, 129 metabolites were selected, and metSS-only models explained 59.0% of the variability in the training cohort and 17.4% in the validation cohort. Regression models including both clinical covariates and the metSS explained more variability than either the clinical covariate or metSS-only models (53.4% vs. 46.4% and 31.6%) in the validation dataset. The metabolomic pathways for arginine biosynthesis; aminoacyl-tRNA biosynthesis; and glycine, serine, and threonine pathway were enriched by adaLASSO metabolites for FEV1. This is the first demonstration of a respiratory metabolomic severity score, which shows how a metSS can add explanation of variance to clinical predictors of FEV1 and MESA-adjusted lung density. The advantage of a comprehensive metSS is that it explains more disease than individual metabolites and can account for substantial collinearity among classes of metabolites. Future studies should be performed to determine whether metSSs are similar in younger, and more racially and ethnically diverse populations as well as whether a metabolomic severity score can predict disease development in individuals who do not yet have COPD.
Associations of the MUC5B promoter variant with timing of interstitial lung disease and rheumatoid arthritis onset
McDermott, Gregory C , Gagne, Staci , Huang, Weixing , Cui, Jing , Prisco, Lauren, Zaccardelli, Alessandra , Kronzer, Vanessa L. , Dellaripa, Paul F. , Doyle, Tracy J. , Sparks, Jeffrey A. , McDermott, Gregory , Cui, Jing , Kronzer, Vanessa L , Sparks, Jeffrey A , Gill, Ritu R. , Byrne, Suzanne , Martin, Lily K. , Moll, Matthew , Cho, Michael H. , Shadick, Nancy A.

Mayo Clinic

Rheumatology | March 15, 2022 | Volume: 61 | Issue: 12 | Pages: 4915-4923

10.1093/rheumatology/keac152 | PMID 35289841 Get It

Abstract Objectives To investigate the associations of the common MUC5B promoter variant with timing of RA-associated interstitial lung disease (RA-ILD) and RA onset. Methods We identified patients with RA meeting 2010 ACR/EULAR criteria and available genotype information in the Mass General Brigham Biobank, a multihospital biospecimen and clinical data collection research study. We determined RA-ILD presence by reviewing all RA patients who had CT imaging, lung biopsy or autopsy results. We determined the dates of RA and RA-ILD diagnoses by manual records review. We examined the associations of the MUC5B promoter variant (G>T at rs35705950) with RA-ILD, RA-ILD occurring before or within 2 years of RA diagnosis and RA diagnosis at age >55 years. We used multivariable logistic regression to estimate odds ratios (ORs) for each outcome by MUC5B promoter variant status, adjusting for potential confounders including genetic ancestry and smoking. Results We identified 1005 RA patients with available genotype data for rs35705950 (mean age 45 years, 79% female, 81% European ancestry). The MUC5B promoter variant was present in 155 (15.4%) and was associated with RA-ILD [multivariable OR 3.34 (95% CI 1.97, 5.60)], RA-ILD before or within 2 years of RA diagnosis [OR 4.01 (95% CI 1.78, 8.80)] and RA onset after age 55 years [OR 1.52 (95% CI 1.08, 2.12)]. Conclusions The common MUC5B promoter variant was associated with RA-ILD onset earlier in the RA disease course and older age of RA onset. These findings suggest that the MUC5B promoter variant may impact RA-ILD risk early in the RA disease course, particularly in patients with older-onset RA.
National Comprehensive Cancer Network investigational drug service consensus recommendations
Amin, Sapna, Polley, Stephen , DeFrates, Sean, Finnes, Heidi D. , Kinsman, Katharine, MacDonald, Elyse A. , Dean, Latanya, DeWitt, Lorri L., Harvey, Caroline , Leung, Tzewah Vivian, Moll, Emily A, O’Neill, Gerald P. , Redic, Kimberly, Park, Sharon F, Harvey, Caroline, Johnston, Susan S.

Mayo Clinic

American Journal of Health-System Pharmacy | December 1, 2021 | Volume: 79 | Issue: 6 | Pages: 486-491

10.1093/ajhp/zxab455 | PMID 34849539 Get It

Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease
Ghosh, Auyon , Hobbs, Brian D. , Moll, M, Saferali, Aabida , Boueiz, Adel , Yun, Jeong H. , Sciurba, Frank, Barwick, Lucas, Flaherty, Kevin, Criner, G J, Brown, Kevin K. , Martinez, Fernando J., Lomas, D M, DeMeo, DL, Silverman, E K, Sciurba, Frank C. , Hoffman, Eric A. , Comellas, Alejandro P. , Lomas, David A. , Rossiter, Harry B. , Ghosh, Auyon J , Wise, Robert , Cho, Michael H , Hersh, Craig P , Yun, Jeong H , Hoffman, Eric A , Comellas, Alejandro P , Hobbs, Brian D , Boueiz, Adel , Limper, Andrew H. , Criner, Gerard J. , Wise, Robert A. , Castaldi, Peter J. , Carey, Vincent J. , Cho, Michael H. , Hersh, Craig P.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | November 11, 2021 | Volume: 205 | Issue: 3 | Pages: 313-323

10.1164/rccm.202106-1404oc | PMID 34762809 Get It

Abstract Rationale Multiple studies have demonstrated an increased risk of chronic obstructive pulmonary disease (COPD) in heterozygous carriers of the AAT (alpha-1 antitrypsin) Z allele. However, it is not known if MZ subjects with COPD are phenotypically different from noncarriers (MM genotype) with COPD. Objectives To assess if MZ subjects with COPD have different clinical features compared with MM subjects with COPD. Methods Genotypes of SERPINA1were ascertained by using whole-genome sequencing data in three independent studies. We compared outcomes between MM subjects with COPD and MZ subjects with COPD in each study and combined the results in a meta-analysis. We performed longitudinal and survival analyses to compare outcomes in MM and MZ subjects with COPD over time. Measurements and Main Results We included 290 MZ subjects with COPD and 6,184 MM subjects with COPD across the three studies. MZ subjects had a lower FEV1% predicted and greater quantitative emphysema on chest computed tomography scans compared with MM subjects. In a meta-analysis, the FEV1was 3.9% lower (95% confidence interval [CI], −6.55% to −1.26%) and emphysema (the percentage of lung attenuation areas <−950 HU) was 4.14% greater (95% CI, 1.44% to 6.84%) in MZ subjects. We found one gene, PGF(placental growth factor), to be differentially expressed in lung tissue from one study between MZ subjects and MM subjects. Conclusions Carriers of the AAT Z allele (those who were MZ heterozygous) with COPD had lower lung function and more emphysema than MM subjects with COPD. Taken with the subtle differences in gene expression between the two groups, our findings suggest that MZ subjects represent an endotype of COPD.
Relationship Between Rheumatoid Arthritis and Pulmonary Function Measures on Spirometry in the UK Biobank
Prisco, Lauren, Wang, Jiaqi , Hobbs, Brian D. , Huang, Weixing , Martin, Lily W., Kronzer, Vanessa L. , Huang, Sicong , Silverman, Edwin K. , Doyle, Tracy J. , Sparks, Jeffrey A. , Kronzer, Vanessa L , Huang, Sicong , Sparks, Jeffrey A , Hobbs, Brian D , Moll, Matthew , Cho, Michael H.

Mayo Clinic

Arthritis & Rheumatology | May 13, 2021 | Volume: 73 | Issue: 11 | Pages: 1994-2002

10.1002/art.41791 | PMID 33982900 Get It

ObjectiveTo investigate the independent relationship of rheumatoid arthritis (RA) to the type and severity of pulmonary patterns on spirometry compared to the pulmonary patterns in general population controls.MethodsIn this cross‐sectional study, we investigated the association of RA with pulmonary function measures on spirometry among subjects in the UK Biobank who underwent spirometry for research purposes. RA cases were identified based on self‐report and current disease‐modifying antirheumatic drug/glucocorticoid use. Controls were subjects without RA from the general population. Outcome measures included continuous forced expiratory volume in 1 second percent predicted (FEV1%) and forced vital capacity percent predicted (FVC%), type of spirometric pattern (restrictive or obstructive), and severity of the restrictive or obstructive pattern. We used multivariable regression to estimate the effects in RA cases compared to the effects in controls, adjusting for age, sex, body mass index, and smoking status/pack‐years.ResultsAmong 350,776 analyzed subjects who underwent spirometry (mean age 56.3 years; 55.8% female; 45.5% ever smokers), we identified 2,008 cases of treated RA. In multivariable analyses, RA was associated with lower FEV1% (β = –2.93 [95% confidence interval (95% CI) –3.63, –2.24]), FVC% (β = –2.08 [95% CI –2.72, –1.45]), and FEV1/FVC (β = –0.008 [95% CI –0.010, –0.005]) compared to controls. RA was additionally associated with restrictive patterns (odds ratio [OR] 1.36 [95% CI 1.21, 1.52]) and obstructive patterns (OR 1.21 [95% CI 1.07, 1.37]) independent of confounders, and was most strongly associated with severe restrictive and obstructive patterns.ConclusionRA is associated with increased odds of restrictive and obstructive patterns, and this relationship is not explained by confounders, including smoking status. In addition to restrictive lung disease, clinicians should also be aware that airway obstruction may be a pulmonary manifestation of RA.
Prediction of Opioid-Induced Respiratory Depression on Inpatient Wards Using Continuous Capnography and Oximetry: An International Prospective, Observational Trial
Uezono, Shoichi , Ti, Lian Kah , McIntyre, Robert C. , Tornero, Carlos , Dahan, Albert , Saager, Leif , Wittmann, Mária , Auckley, Dennis , Soto, Roy G. , Schramm, Frank, Ayad, Sabry , Kaw, Roop , Stefano, Paola Di, Moll, Vanessa , Dempsey, Susan J., Bühre, Wolfgang , Overdyk, Frank J. , Collaborators, on behalf of the PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) Group, Fiorda‐Diaz, Juan , Khanna, Ashish K. , Bergese, Sergio D. , Jungquist, Carla R. , Morimatsu, Hiroshi , Lee, Simon , Urman, Richard D , Weingarten, Toby N. , Brazzi, Luca , Guen, Morgan Le , Schramm, Frank, Sessler, Daniel I. , Uribe, Alberto A. , Collaborators, on behalf of the PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) Group, Law, Lawrence Siu‐Chun

Mayo Clinic

Anesthesia & Analgesia | April 18, 2020 | Volume: 131 | Issue: 4 | Pages: 1012-1024

10.1213/ane.0000000000004788 | PMID 32925318 Get It

BACKGROUND: Opioid-related adverse events are a serious problem in hospitalized patients. Little is known about patients who are likely to experience opioid-induced respiratory depression events on the general care floor and may benefit from improved monitoring and early intervention. The trial objective was to derive and validate a risk prediction tool for respiratory depression in patients receiving opioids, as detected by continuous pulse oximetry and capnography monitoring. METHODS: PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) was a prospective, observational trial of blinded continuous capnography and oximetry conducted at 16 sites in the United States, Europe, and Asia. Vital signs were intermittently monitored per standard of care. A total of 1335 patients receiving parenteral opioids and continuously monitored on the general care floor were included in the analysis. A respiratory depression episode was defined as respiratory rate ≤5 breaths/min (bpm), oxygen saturation ≤85%, or end-tidal carbon dioxide ≤15 or ≥60 mm Hg for ≥3 minutes; apnea episode lasting >30 seconds; or any respiratory opioid-related adverse event. A risk prediction tool was derived using a multivariable logistic regression model of 46 a priori defined risk factors with stepwise selection and was internally validated by bootstrapping. RESULTS: One or more respiratory depression episodes were detected in 614 (46%) of 1335 general care floor patients (43% male; mean age, 58 ± 14 years) continuously monitored for a median of 24 hours (interquartile range [IQR], 17–26). A multivariable respiratory depression prediction model with area under the curve of 0.740 was developed using 5 independent variables: age ≥60 (in decades), sex, opioid naivety, sleep disorders, and chronic heart failure. The PRODIGY risk prediction tool showed significant separation between patients with and without respiratory depression ( P < .001) and an odds ratio of 6.07 (95% confidence interval [CI], 4.44–8.30; P < .001) between the high- and low-risk groups. Compared to patients without respiratory depression episodes, mean hospital length of stay was 3 days longer in patients with ≥1 respiratory depression episode (10.5 ± 10.8 vs 7.7 ± 7.8 days; P < .0001) identified using continuous oximetry and capnography monitoring. CONCLUSIONS: A PRODIGY risk prediction model, derived from continuous oximetry and capnography, accurately predicts respiratory depression episodes in patients receiving opioids on the general care floor. Implementation of the PRODIGY score to determine the need for continuous monitoring may be a first step to reduce the incidence and consequences of respiratory compromise in patients receiving opioids on the general care floor.